{"entity":{"id":"nct06952803","kind":"trial","name":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","aka":["EvoPAR-Prostate02"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06952803 as recruiting, last updated 2026-09-18. Enrolment is 700 planned participants, an estimate. Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT). Primary measures include Metastasis-free survival (MFS). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06952803","url":"https://clinicaltrials.gov/study/NCT06952803"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-high-risk"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06952803","phase":"3","setting":"A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).","sponsor":"AstraZeneca","participation":[{"nct":"NCT06952803","source":"https://clinicaltrials.gov/study/NCT06952803","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"4e5ded2048ab8220a58882d18807ca35fee6cbe4ad79d4e140371cbde4391ad9","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-18","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":700,"enrolmentType":"ESTIMATED","siteCount":346,"recruitingSiteCount":260,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Finland","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Netherlands","Peru","Poland","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-08-06","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06952803/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}